Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

NCT01775124 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab

Sponsor

Novartis Pharmaceuticals